OTTAWA, April 17, 2015 /CNW/ -
The issue:
In consultation with Health Canada, GlaxoSmithKline Inc. (GSK) is voluntarily recalling one lot (lot 710535) of Clavulin-400 (70mL) after receiving a complaint from a pharmacy that two glass pieces had been found in one bottle of the product. No other lots of GSK Clavulin products are affected at this time.
Clavulin-400 is an oral antibiotic used in adults and children aged 12 weeks and older to treat various bacterial infections. Clavulin-400 comes as a powder in bottles and is mixed with purified water by a pharmacist before dispensing. The mixed product is a liquid taken by mouth and can be stored refrigerated for seven days.
Products affected:
Who is affected: Consumers including parents and caregivers who have purchased or used Clavulin-400 or who have provided it to their children.
What consumers should do:
What Health Canada is doing:
Health Canada is monitoring the recall and the company's preventative and corrective actions and will inform Canadians should new safety information become available.
Background:
GSK advised Health Canada that they received a complaint from a pharmacy that had identified two pieces of glass in one bottle of Clavulin-400 (Lot 710535). According to GSK, a total of 29,949 bottles from the affected lot (Lot 710535) have been distributed in Canada since March 10, 2015. This is the only complaint GSK has received of this nature.
Since the product is prepared and dispensed by a pharmacist, the potential for accidental ingestion of the glass particles is very remote. Risks associated with ingestion of a sharp piece of glass potentially include choking, stomach pain, vomiting, cuts, and blockage or holes in the esophagus or gastrointestinal tract.
How to report side effects to health products to Health Canada:
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.
Également disponible en français
SOURCE Health Canada
PDF available at: http://stream1.newswire.ca/media/2015/04/17/20150417_C8271_PDF_EN_14432.pdf
Media Enquiries: Health Canada, (613) 957-2983; Public Enquiries: (613) 957-2991, 1-866 225-0709
Share this article